Sequana Medical NV (EBR: SEQUA)

Market Cap	113.76M
Revenue (ttm)	433.50K
Net Income (ttm)	-27.18M
Shares Out	44.44M
EPS (ttm)	-0.90
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	39,805
Average Volume	817,077
Open	2.560
Previous Close	2.560
Day's Range	2.560 - 2.680
52-Week Range	0.471 - 4.400
Beta	0.30
RSI	54.68
Earnings Date	Mar 25, 2025

About Sequana Medical NV

Sequana Medical NV develops and commercializes treatments for patients with diuretic-resistant fluid overload in liver disease, cancer, and heart failure in Belgium, Germany, France, Switzerland, and internationally. The company products pipeline comprises alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; and Direct Sodium Removal (DSR) for the treatment of fluid overload spread across the body and heart failure. Sequana Medical NV was founded in 2006 and is headquartered in Gent, B...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2006
• Employees: 62
• Stock Exchange: Euronext Brussels
• Ticker Symbol: SEQUA

Financial Performance

In 2023, Sequana Medical NV's revenue was 712,173, a decrease of -22.82% compared to the previous year's 922,687. Losses were -32.56 million, 5.85% more than in 2022.